Sherwood MW, et al. - Researchers used the NCDR STS/ACC TVT Registry to analyze contemporary practice patterns of antiplatelet therapy and their association with post-TAVR outcomes. They assessed dual antiplatelet therapy (DAPT) use in patients without anticoagulation as the primary outcome. They also evaluated death, major bleeding, myocardial infarction, and stroke at 1 year. They found that most of the patients who underwent TAVR were discharged on DAPT in the US, though there was significant variance in practice patterns among hospitals. Findings also revealed that, vs antiplatelet monotherapy, a similar adjusted risk of mortality, stroke and MI, but significantly higher risk for bleeding was observed among patients discharged with DAPT.